New study tracks Real-World impact of targeted radiation on tough prostate cancers
NCT ID NCT07290270
First seen Jan 05, 2026 · Last updated May 21, 2026 · Updated 21 times
Summary
This study follows 170 men in China with metastatic prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how much PSA levels drop, how long the cancer stays controlled, and how patients feel during and up to a year after treatment. The goal is to see how well this therapy works outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGShanghai, Shanghai Municipality, China, China
Conditions
Explore the condition pages connected to this study.